London · Delayed Price · Currency is GBP · Price in GBX Poolbeg Pharma Statistics
Total Valuation
Poolbeg Pharma has a market cap or net worth of GBP 47.36 million. The enterprise value is 42.54 million.
| Market Cap | 47.36M |
| Enterprise Value | 42.54M |
Important Dates
The next estimated earnings date is Friday, December 18, 2026.
| Earnings Date | Dec 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Poolbeg Pharma has 763.44 million shares outstanding. The number of shares has increased by 39.33% in one year.
| Current Share Class | 763.44M |
| Shares Outstanding | 763.44M |
| Shares Change (YoY) | +39.33% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 16.74% |
| Owned by Institutions (%) | 46.36% |
| Float | 556.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.28 |
| P/TBV Ratio | 9.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.44
| Current Ratio | 12.44 |
| Quick Ratio | 11.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.55% and return on invested capital (ROIC) is -40.53%.
| Return on Equity (ROE) | -58.55% |
| Return on Assets (ROA) | -38.73% |
| Return on Invested Capital (ROIC) | -40.53% |
| Return on Capital Employed (ROCE) | -90.09% |
| Weighted Average Cost of Capital (WACC) | 14.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -363,800 |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -61,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.14% in the last 52 weeks. The beta is 1.84, so Poolbeg Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | +77.14% |
| 50-Day Moving Average | 8.08 |
| 200-Day Moving Average | 6.00 |
| Relative Strength Index (RSI) | 25.11 |
| Average Volume (20 Days) | 2,478,384 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.05M |
| Pretax Income | -5.52M |
| Net Income | -5.46M |
| EBITDA | -5.98M |
| EBIT | -6.05M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 4.82 million in cash and no debt, with a net cash position of 4.82 million or 0.01 per share.
| Cash & Cash Equivalents | 4.82M |
| Total Debt | n/a |
| Net Cash | 4.82M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 6.71M |
| Book Value Per Share | 0.01 |
| Working Capital | 5.02M |
Cash Flow
| Operating Cash Flow | -5.23M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 70,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -5.23M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Poolbeg Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -39.33% |
| Shareholder Yield | -39.33% |
| Earnings Yield | -11.17% |
| FCF Yield | -10.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |